
Daily dose of baby aspirin can halve your chances of getting colorectal cancer if you have this condition
Could a pill a day keep polyps at bay?
A new study suggests that a daily dose of aspirin could help ward off colorectal cancer in people with a rare genetic disorder that increases their risk of developing the disease.
Better yet, British researchers found that low doses of the over-the-counter drug offer the same protection as higher ones — with fewer side effects.
Advertisement
4 Several studies have linked long-term aspirin use to a lower risk of colorectal cancer and polyps.
Stefan – stock.adobe.com
The study involved nearly 1,900 people with Lynch syndrome, a hereditary condition that significantly raises the risk of several cancers, especially colorectal and endometrial.
Though it affects an estimated 1.1 million Americans, fewer than 5% know they carry the genetic mutation, according to the National Cancer Institute.
Advertisement
Previous research found that a daily 600 milligram aspirin dose could cut colorectal cancer risk in people with Lynch syndrome by half.
However, high doses can cause side effects like stomach pain, ulcers and bleeding, which have made some patients reluctant to continue with the preventive treatment.
4 Aspirin can cause uncomfortable side effects when taken at high doses.
Liubomir – stock.adobe.com
This time, scientists at Newcastle University in the UK split participants with Lynch syndrome into three groups, each taking 100mg, 300mg or 600mg of aspirin daily for five years.
Advertisement
By the end of the study, there were fewer colorectal cancer cases in all three groups, but those taking the lowest dose got the same protection with fewer side effects.
'We now have really good evidence that aspirin can prevent bowel cancer in those at a high risk of the disease,' said Dr. David Crosby, head of prevention and early detection research at Cancer Research UK.
4 Colorectal cancer is the second leading cause of cancer deaths in the US.
Jo Panuwat D – stock.adobe.com
Advertisement
The average American's lifetime risk of colorectal cancer is about 5%, but those with Lynch syndrome face a staggering 40% to 80% risk, according to MD Anderson Cancer Center.
The National Comprehensive Cancer Network recommends that people with Lynch syndrome take aspirin daily to reduce their chances of developing cancer.
However, studies show only about 34% follow this advice — often due to concerns about side effects.
'Too many people are missing out on a potentially life-changing opportunity to prevent cancer,' said Sir John Burn, professor of clinical genetics at Newcastle University and lead author of the study.
'We have a chance to give more people with Lynch syndrome protection, which would reduce their fear of bowel cancer in the future.'
4 Lynch syndrome is passed down through families via a gene mutation.
Dana Farber Cancer Institute
Lynch syndrome is the most common cause of hereditary colorectal cancer in the US, with data showing that it accounts for about 3,800 cases each year.
Advertisement
Colon cancers tied to the genetic disorder tend to develop far faster than in the general population — often within one to two years versus about 10 years, according to the Cleveland Clinic.
To make matters worse, those diagnosed with colorectal cancer linked to Lynch syndrome are more likely to face a relapse down the line.
'People with Lynch syndrome get regular colonoscopies and live with the anxiety that they are highly likely to develop bowel cancer in their lifetime,' Crosby said.
'Taking aspirin daily could cut this risk by at least half and alleviate their fears,' he added.
Advertisement
Once a disease that primarily affected older adults, colorectal cancer cases have surged among younger Americans in recent years.
It's now the fourth most commonly diagnosed cancer in the US, and the second leading cause of cancer death nationwide, according to the Colorectal Cancer Alliance.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


UPI
an hour ago
- UPI
Senate confirms Dabbar as Commerce Department deputy secretary
1 of 3 | Paul Dabbar testifies at his confirmation hearing as the deputy secretary of Commerce with the Senate Commerce, Science and Transportation committee in the Russell Senate office building in Washington, D.C., on May 1. File Photo by Annabelle Gordon/UPI | License Photo June 25 (UPI) -- The Senate on Wednesday voted 56-40 to confirm Paul Dabbar as the deputy secretary of the Commerce Department. Dabbar will serve as the Commerce Department's chief operating officer and oversee its $11.4 billion annual budget across its 12 units and the department's 47,000 employees. Science and technology are "fundamental to shaping our nation's future," Dabbar said. "As a scientist, I'm eager to work alongside the dedicated teams and partners across the department to accelerate research and drive innovation," he added. The Senate confirmation also makes Dabbar a member of the President's Management Council. "Paul brings a unique science-backed mindset and deep understanding of how the government and industry can work together to push the boundaries of American innovation and technology," Commerce Secretary Howard Lutnick said. "His leadership will be critical in advancing cutting-edge research and technology," Lutnick added. Dabbar was the president and chief executive officer of Bohr Quantum Technology prior to his Senate confirmation. He led the development and deployment of emerging quantum network technologies while at Bohr. During President Donald Trump's first administration, Dabbar was the science under secretary at the Department of Energy and led energy research, technologies and science initiatives. He also managed and led most of the U.S. national labs, including those involving nuclear energy, advanced computing, quantum technologies, fusion and physics. Dabbar also was a managing director at J.P. Morgan, where he spearheaded more than $400 billion in global energy sector investments.


Newsweek
2 hours ago
- Newsweek
Ozempic Linked to Significant Reduction in Dementia—Study
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Semaglutide, the active ingredient in diabetes medications Ozempic and Wegovy, was associated with a significantly reduced risk of developing Alzheimer's disease-related dementia among patients with type 2 diabetes, a recent study reported. A new study published in the Journal of Alzheimer's Disease analyzed the medical records of over 1.7 million U.S. adults and found that semaglutide users experienced a notably lower risk of dementia compared to patients treated with insulin, metformin, or older GLP-1 agonists. These findings, publicly released on Tuesday, come as researchers and clinicians continue to search for effective means to mitigate the growing dementia epidemic in the U.S. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. Photo by Steve Christo - Corbis/Corbis via Getty Images Why It Matters With over 6 million Americans diagnosed with dementia and more than 100,000 related deaths each year, the potential for semaglutide to meaningfully lower risk could have sweeping public health implications. Dementia does not have a cure, and nearly half of all cases are thought to be preventable by addressing risk factors like obesity, type 2 diabetes, and cardiovascular disease, the New York Post reported. Evidence supporting semaglutide's neuroprotective effects may inform future prevention strategies among high-risk populations in the U.S. What To Know Landmark Study Shows Sharp Risk Reduction Researchers at Case Western Reserve School of Medicine, National Institutes of Health and the MetroHealth System in Cleveland examined the health records of 1,710,995 U.S. patients with type 2 diabetes who had no prior diagnosis of Alzheimer's disease-related dementia (ADRD). The study used a statistical method simulating a randomized clinical trial, comparing dementia diagnoses among those prescribed semaglutide, insulin, metformin, and older GLP-1 receptor agonists. Patients treated with semaglutide had a 46 percent lower risk of developing ADRD than those receiving insulin, a 33 percent lower risk than those on metformin, and a 20 percent lower risk than those on earlier GLP-1 agonists. The effect was particularly pronounced for vascular dementia, one of the most common subtypes. No protective association was found for frontotemporal dementia or Lewy body dementia. Wide Demographic Impact Observed The protective association was consistent among subgroups, including younger and older patients, men and women, and those with and without obesity. Researchers found the risk reduction was especially evident among older adults and women. What is Semaglutide? Semaglutide is a glucagon-like peptide-1 receptor agonist that helps regulate blood sugar, lowers body weight, and offers cardiovascular benefits for patients with diabetes. The drug can help improve insulin sensitivity, protect blood vessels, and reduce inflammation in the brain. Important Study Limitations Authors acknowledged limitations, including reliance on administrative diagnosis codes, which are subject to underdiagnosis and misclassification, data on medication adherence, cognitive test scores, and genetic risk factors were unavailable. Variations in clinical practice and health care use variations could also affect findings. Researchers emphasized the need for preclinical and clinical studies to establish causal effects. Additional International Data A separate study by Oxford University, published in Lancet's eClinicalMedicine journal, analyzed more than 100 million U.S. medical records and found that Ozempic users experienced lower rates of cognitive decline and nicotine use compared to those on other diabetes medications. This study also did not find a higher risk of anxiety, depression, or other neurological and psychiatric conditions with Ozempic. The researchers emphasized that the results were limited to diabetic patients and require more rigorous randomized controlled trials. What People Are Saying The researchers of the study, in a news article published by the American Journal of Managed Care: "In a real-world population with T2D [type 2 diabetes] who had no prior diagnosis of AD/ADRD [Alzheimer disease/Alzheimer disease-related dementia], our study shows that semaglutide was associated with a significantly lower risk of overall ADRD incidence compared with other antidiabetic medications, including insulin, metformin, and other GLP-1RAs. Significant reductions were observed in older and younger patients, women and men, and patients with and without obesity." Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, in comments to Reuters: "The answer to all those limitations is to do a randomized clinical trial, which is exactly what Novo is doing." What Happens Next Novo Nordisk, the maker of Ozempic, began testing semaglutide in patients with early Alzheimer's disease in 2021. The results are expected sometime this year. Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@


Chicago Tribune
3 hours ago
- Chicago Tribune
Nestle says it will remove artificial dyes from US foods by 2026
Nestle said Wednesday it will eliminate artificial colors from its U.S. food and beverages by the middle of 2026. It's the latest big food company making that pledge. Last week, Kraft Heinz and General Mills said they would remove artificial dyes from their U.S. products by 2027. General Mills also said it plans to remove artificial dyes from its U.S. cereals and from all foods served in K-12 schools by the middle of 2026. The move has broad support. About two-thirds of Americans favor restricting or reformulating processed foods to remove ingredients like added sugar or dyes, according to an AP-NORC poll. Both California and West Virginia have recently banned artificial dyes in foods served in schools. On Sunday, Republican Gov. Greg Abbott of Texas signed a bill requiring foods made with artificial dyes or additives to contain a new safety label starting in 2027. The label would say they contain ingredients 'not recommended for human consumption' in Australia, Canada, the European Union or the U.K. The federal government is also stepping up its scrutiny of artificial colors. In January, days before President Donald Trump took office, the U.S. regulators banned the dye called Red 3 from the nation's food supply, nearly 35 years after it was barred from cosmetics because of potential cancer risk. In April, Trump's Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said the agency would take steps to eliminate synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Nestle has pledged to remove artificial dyes before. Early in 2015, the company said it would remove artificial flavors and colors from its products by the end of that year. But the promise didn't hold. Nestle said Wednesday it's been removing synthetic dyes from its products over the last decade, and 90% of its U.S. portfolio doesn't contain them. Among those that do is Nesquik Banana Strawberry milk, which is made with Red 3. Nestle said Wednesday it wants to evolve with its U.S. customers' changing nutritional needs and preferences. 'Serving and delighting people is at the heart of everything we do and every decision that we make,' Nestle's U.S. CEO Marty Thompson said in a statement.